The patterns of tumor evolution during metastatic progression and the associated clinical outcome for a cancer patient depend on the immune contexture at the site of metastasis. Defining the immune contexture of a cancer—determined by the density, composition, functional state, and organization of the leukocyte infiltrate of the tumor—can yield information relevant to the prediction of the treatment response and the patient’s prognosis. The development of multiplex immunofluorescence (mIF) technologies enables spatial phenotyping of the tumor microenvironment (TME), which aids in defining the immune contexture through a quantitative assessment of immune phenotypes and functional orientation of immune cells, while simultaneously providing tissue context and spatial distribution within the TME.
Recent studies strongly suggest the importance of determining a patient’s Immunoscore as well as the need for a more comprehensive understanding, both spatially and functionally, of the simultaneous presence of multiple immune cell types within the TME. Immune contexture parameters, including the Immunoscore, have a prognostic, predictive, and mechanistic value. Once identified, the key immune elements should be translated into clinically feasible treatment protocols, integrating with the field of immunopathology.
In this webinar, our expert speaker will:
- Describe how a spatial phenotyping approach has supported the development of Immunoscore to estimate the prognosis of colorectal cancer patients
- Explain how spatial phenotyping enables researchers to assess pre-existing, intratumor adaptive immune responses for developing more effective immunotherapies, such as the use of checkpoint inhibitors
- Offer insights into how a combination of multiple immune parameters might provide increased prognostic and/or predictive power
- Answer questions during the live presentation.
This webinar will last for approximately 60 minutes.